

7. Singh N. Universal prophylaxis versus preemptive therapy for cytomegalovirus prophylaxis in organ transplant recipients. *Clin Infect Dis* **2001**; 32:742–51.
8. Potena L, Holweg CT, Chin C. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus. *Transplantation* **2006**; 82:398–405.
9. Razonable RR, van Crujisen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. *J Infect Dis* **2003**; 187:1801–8.
10. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. *Am Heart J* **1999**; 138:S469–72.
11. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. *Liver Transpl* **2008**; 14:240–2.
12. Kim DH, Won DI, Lee NY, et al. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation. *Transplantation* **2006**; 81:101–8.
13. Scholz D, Arndt R, Meyer R. Evidence for an immunosuppressive activity of ganciclovir. *Transplant Proc* **1994**; 26:3253–4.
14. Steininger C, Kundi M, Kletzmayer J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. *J Infect Dis* **2004**; 190:1908–12.
15. Kijpittayarit S, Deziel P, Eid AJ, Razonable RR. Primary cytomegalovirus disease after 5 years of antiviral prophylaxis. *Transplantation* **2006**; 81:137–8.

Reprints or correspondence: Dr. Nina Singh, Infectious Diseases Section, VA Medical Center, University Drive C, Pittsburgh, PA 15240 (nis5@pitt.edu).

Clinical Infectious Diseases **2008**; 47:296–7

© 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4702-0031\$15.00

DOI: 10.1086/589577

Reply to Singh

TO THE EDITOR—We read the letter from Singh [1] with great interest, because she outlined several important issues that may not be easy to clarify. The recent article by Arthurs et al. [2], which was not available when we wrote our review, suggests that late-onset cytomegalovirus (CMV) disease may not be as mild as has been previously reported by others. In our long-lasting experience with anti-CMV prophylaxis [3], late-onset CMV disease was perceived and evaluated as a relatively

mild event, at least in kidney transplant recipients, with few symptoms and a benign course after receipt of ganciclovir or valganciclovir therapy. It should be noticed that the figures reported by Arthurs et al. [2] were unusually high: a 29% incidence of late-onset CMV disease, compared with incidences of 16% in the valganciclovir group in the study by Lowance et al. [3] and 17.2% (in the valganciclovir group) and 18.4% (in the oral ganciclovir group) in the pivotal study by Paya et al. [4]. In our own experience, 17% of kidney transplant recipients develop late-onset CMV disease (data not shown). Although the cause is not clear (because these transplant recipients were at high immunological risk), the relatively high figures reported by Arthurs et al. [2] may have affected the results regarding the impact of late-onset CMV in terms of allograft loss or mortality.

The discussion about the consequences of late-onset CMV disease is more than an academic debate. Indeed, it is aimed at answering relevant questions regarding the best means to prevent post-transplantation CMV disease. Data from a recent meta-analysis indicated that both prophylaxis and preemptive treatment reduced the incidence of CMV disease and of acute transplant rejection; however, prophylaxis without preemptive treatment did reduce the incidence of bacterial and fungal infections and death [5]. When prophylaxis and preemptive treatments were compared with one another, there was, indeed, no statistically significant difference with regard to efficacy in the prevention of CMV disease [6, 7]. However, in the study by Reischig et al. [6], there were slight and statistically significant benefits in the prophylaxis group with regard to CMV-DNAemia at 12 months, incidence of biopsy-proven acute rejection, and CMV-associated costs. Moreover, in the recent study by Kliem et al. [7], long-term graft survival at 2, 3, and 4 years was significantly improved in the prophylaxis group. These recent data, together with the simple use of prophylaxis after transplan-

tation, suggest that the prophylactic approach may become a more attractive strategy to prevent CMV disease after organ transplantation.

Finally, as mentioned by Singh [1], the issue of the most appropriate duration of antiviral prophylaxis will be partly solved by the ongoing Improved Protection Against Cytomegalovirus in Transplant (IMPACT) study. If, among high-risk patients undergoing donor-positive/recipient-negative transplantations, the incidence of late-onset CMV disease decreases as the length of anti-CMV prophylaxis increases, this may have a beneficial impact on morbidity and mortality that would be an important new step in defining the optimal CMV disease prevention strategies.

Acknowledgments

Potential conflicts of interest. C.L. and M.P. have received unrestricted grants from Roche, Novartis, Astrella, and Wyeth.

Christophe Legendre¹ and Manuel Pascual²

¹Service de Transplantation Rénale Adulte, Hôpital Necker & Université Paris Descartes, Paris, France; and ²Transplantation Center, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

References

1. Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients. *Clin Infect Dis* **2008**; 47:296–7 (in this issue).
2. Arthurs S, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. *Clin Infect Dis* **2008**; 46: 840–6.
3. Lowance D, Neumayer HH, Legendre C, et al. Valganciclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valganciclovir Cytomegalovirus Prophylaxis Transplantation Study Group. *N Engl J Med* **1999**; 340:1462–70.
4. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant* **2004**; 4:611–20.
5. Kallil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. *Ann Intern Med* **2005**; 143:870–80.
6. Reischig T, Jindra P, Hes O, Svecova M, Kloboch J, Treska V. Valganciclovir prophylaxis versus preemptive valganciclovir therapy to pre-

- vent cytomegalovirus disease after renal transplantation. *Am J Transplant* **2007**;7:1–9.
7. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. *Am J Transplant* **2008**;8:975–83.

Reprints or correspondence: Dr. Christophe Legendre, Service de Transplantation Rénale Adulte, Hôpital Necker and Université Paris Descartes, 149, rue de Sèvres, 75015 Paris, France (christophe.legendre@nck.aphp.fr).

Clinical Infectious Diseases **2008**;47:297–8

© 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4702-0032\$15.00
DOI: 10.1086/589578